Core Viewpoint - Junshi Biosciences (01877) expects to achieve approximately 2.5 billion yuan in revenue for the year 2025, representing a year-on-year growth of about 28.32% [1] Financial Performance - The projected R&D expenses for 2025 are approximately 1.353 billion yuan, reflecting a year-on-year increase of about 6.10% [1] - The expected net loss attributable to the parent company for 2025 is around 873 million yuan, a reduction of approximately 31.85% compared to the previous year [1] - After excluding the impact of share-based payments, the net loss is projected to be about 799 million yuan, a decrease of approximately 37.62% year-on-year [1] - The net loss after excluding non-recurring gains and losses is expected to be around 985 million yuan, down about 23.64% year-on-year [1] - The net loss after excluding both share-based payments and non-recurring items is projected to be approximately 911 million yuan, a reduction of about 29.37% year-on-year [1] Product and Market Development - The increase in revenue is primarily due to the growth in sales of commercialized drugs, particularly the core product Toripalimab injection (brand name: Tuoyi®), which saw significant sales growth in the domestic market [1] - As of the announcement date, Tuoyi® has been approved for 12 indications in mainland China, all of which are included in the national medical insurance catalog, making it the only anti-PD-1 monoclonal antibody for treating renal cancer, triple-negative breast cancer, and melanoma in the catalog [1] - The company continues to expand its global commercialization network, with Toripalimab approved in over 40 countries and regions, including mainland China, Hong Kong, the United States, the EU, India, the UK, Jordan, Australia, Singapore, the UAE, Kuwait, Pakistan, Canada, and Bahrain [2] Strategic Initiatives - Despite the expected net loss, the company has significantly narrowed its loss compared to the previous year, mainly due to the implementation of the "quality improvement and efficiency enhancement" action plan, which has improved commercialization capabilities while strengthening cost control and resource focus [2] - The company is advancing its core pipeline efficiently while controlling expenses, rapidly progressing clinical trials for several innovative drugs with international market competitiveness, including JS207 (PD-1/VEGF dual antibody), JS212 (EGFR/HER3 ADC), and JS213 (PD-1/IL-2 fusion protein) [2] - JS207 is currently in Phase II clinical trials, exploring combinations with chemotherapy, monoclonal antibodies, ADCs, and other drugs across multiple tumor types, with ongoing Phase II trials for the combination of JS207 and JS212 [2] - The company aims to accelerate pipeline development and push more advantageous products and indications into the registration clinical trial phase as soon as possible [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2026年1月30日 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司2025年年度業績預告》，僅供參閱。 承董事會命 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 证券代码：688180 证券简称：君实生物 公告编号：临 2026-00 ...

每经AI快讯，君实生物1月30日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利 润-8.73亿元左右，与上年同期相比亏损减少约4.08亿元左右，同比亏损减少31.85%左右。业绩变动主要 原因是，报告期内，公司营业收入增长，主要系商业化药品的销售收入与上年同期相比有所增长。 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 ...

Group 1 - The top three companies with the highest short position ratios are China COSCO Shipping (01919) at 17.74%, Vanke (02202) at 17.56%, and Dongfang Electric (01072) at 17.36% [1][2] - The companies with the largest absolute increase in short position ratios are Neway Group (01686) with an increase of 2.33%, China Ship Leasing (03877) with an increase of 2.23%, and Pacific Shipping (02343) with an increase of 1.78% [1][2] - The companies with the largest absolute decrease in short position ratios are Zhaoyan New Drug (06127) with a decrease of -1.92%, Lens Technology (06613) with a decrease of -1.51%, and Country Garden (02007) with a decrease of -1.48% [1][3] Group 2 - The latest short position ratios for the top ten companies show China COSCO Shipping (01919) at 17.74%, Vanke (02202) at 17.56%, and Dongfang Electric (01072) at 17.36% [2] - The companies with the largest increases in short position ratios include Neway Group (01686) from 3.65% to 5.99%, China Ship Leasing (03877) from 0.74% to 2.97%, and Pacific Shipping (02343) from 5.02% to 6.80% [2] - The companies with the largest decreases in short position ratios include Zhaoyan New Drug (06127) from 7.94% to 6.02%, Lens Technology (06613) from 8.32% to 6.80%, and Country Garden (02007) from 3.02% to 1.54% [3][4]

证券代码：688180 证券简称：君实生物 公告编号：临 2026-003 上海君实生物医药科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经财务部门初步测算，预计 2025 年年度实现营业收入 250,000.00 万元左 右，与上年同期相比增长 55,168.27 万元左右，同比增长 28.32%左右。 2、预计 2025 年年度研发费用为 135,300.00 万元左右，与上年同期相比增长 7,772.99 万元左右，同比增长 6.10%左右。 3、预计 2025 年年度实现归属于母公司所有者的净利润-87,300.00 万元左右， 与上年同期相比亏损减少 40,792.64 万元左右，同比亏损减少 31.85%左右。预计 2025年年度扣除股份支付影响后实现归属于母公司所有者的净利润-79,900.00万 元左右，与上年同期相比亏损减少 4 ...

以下为2025年度新质100创新企业榜： 360集团 爱美客 百川智能 柏垠生物 达梦数据 海光信息 华硼中子 极智嘉科技 佳杰云星 金山办公 君实生物 科曼医疗 莱芒生物 老来健康 凌雄科技 Mirxes觅瑞 墨芯人工智能 欧冶半导体 擎朗智能 週届日日 安恒信息 百度慧播星 北京人形 丹诺医药 海康威视 华为终端 剂泰科技 箭元科技 京北方 康盈半导体 快看漫画 蓝箭航天 理工雷科 蚂蚁集团 壓尔线程 默达生物 普瑞基准 深睿医疗 爱连健康 奧比中光 百利天恒 长生医疗 国泰海通证券 寒武纪 火石创造 加速进化 会蝶集团 京东科技 科大讯飞 快手科技 浪潮海岳HOM 立康生命科技 Medidata 魔法原子 纳安生物 阡视科技 深之蓝 1月30日，由经济观察报社举办的2025年度创新峰会成功举办。此次峰会以 "新质领航 创启未来" 为主题，汇聚多名企业家、学者及行业领袖，围 绕人工智能、数字化转型、机器人、生物医药等热点领域，分享前沿动态与创新实践。 随着全球产业竞争进入 "创新竞速、集群突破" 的新阶段，中国正以 "新质生产力" 突破传统增长路径 —— 人工智能重构产业效率、半导体芯片 打破技术壁垒、空 ...

Core Insights - The 2025 Innovation Summit, hosted by Economic Observer, focused on themes such as artificial intelligence, digital transformation, robotics, and biomedicine, gathering entrepreneurs, scholars, and industry leaders to share cutting-edge developments and innovative practices [1] - China is entering a new phase of global industrial competition characterized by "innovation racing and cluster breakthroughs," with "new quality productivity" reshaping traditional growth paths through advancements in AI, semiconductor technology, aerospace economy, robotics, and biomedicine [1] - The summit highlighted 20 leading companies recognized for their technological advancements and contributions to industry ecosystems, serving as benchmarks for innovation and value realization during the 14th Five-Year Plan period [1] Industry Highlights - The development of new quality productivity is transitioning from single-point technological breakthroughs to deep integration within industrial scenarios, emphasizing the need for solid innovative practices and implementable development paradigms [1] - The summit introduced the "Qianxing List" featuring outstanding innovative enterprises and benchmark practices, showcasing the industry's core strengths and innovative capabilities [1] Company Case Studies - Bai Li Tian Heng's transformation practice was highlighted as a significant case [3] - The Iza-Bren dual-antibody ADC research project aims to fill treatment gaps for multiple tumor types, leading global breakthroughs in innovative oncology drugs [4] - Huawei's business attribute-based monitoring solution for the securities industry was presented as a key innovation [5] - The Wangdong health management solution case from Wenzhou People's Hospital was showcased by Huawei [6] - Kingsoft Office's WPS 365 smart education platform was recognized for empowering digital upgrades in higher education [7] - JD Technology's AI innovation practices in government services were also featured [7] - The establishment of a commercial production line EBR system by iFlytek aims to empower high-quality development in the biomedicine industry through digital upgrades [8] - iFlytek's Starfire large model demonstrates full-scenario penetration and value creation [9] - Kuaishou Technology's AI-assisted interactive comics address pain points in AI companionship, creating a new upgraded paradigm for comic experiences [10] - Ant Group's technological breakthroughs and commercialization practices in AI were highlighted [11] - Qianshi Technology's Lingguang App leads a new paradigm for multimodal AI assistants [12] - Schneider Electric's WYLON® large model integrated machine showcases innovative practices [13] - Yiling Pharmaceutical's predictive maintenance system based on multimodal large models demonstrates technological breakthroughs and scalable applications [14]

Group 1 - The top three companies with the highest AH premium rates are Northeast Electric (00042) at 831.03%, Zhejiang Shibao (01057) at 339.32%, and Sinopec Oilfield Service (01033) at 323.71% [1][2] - The bottom three companies with the lowest AH premium rates are CATL (03750) at -14.62%, China Merchants Bank (03968) at -3.22%, and Hengrui Medicine (01276) at 1.77% [1][2] - Sinopec Oilfield Service (01033), Andeli Juice (02218), and Shandong Molong (00568) have the highest deviation values at 53.41%, 21.68%, and 19.01% respectively [1][2] Group 2 - The companies with the lowest deviation values include Zhejiang Shibao (01057) at -58.91%, Yangtze Optical Fibre and Cable (06869) at -49.00%, and Fudan Zhangjiang (01349) at -24.81% [1][2][4] - The top ten AH stocks by premium rate include companies like Hongye Futures (03678) and Beijing Electromechanical (00187) with premium rates of 258.91% and 257.99% respectively [2] - The bottom ten AH stocks by premium rate include Weichai Power (02338) and Midea Group (00300) with premium rates of 6.84% and 8.51% respectively [2]

Core Insights - The report highlights significant changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2]. Group 1: Companies with Increased Holdings - Nanhua Futures (02691) saw the largest increase in holdings, up by 4.45% to a total of 10.44% [2]. - Junshi Biosciences (01877) experienced a 2.39% increase, bringing its total holding to 55.84% [2]. - Lion Group (02562) had a 2.21% increase, resulting in a holding of 53.31% [2]. - Other notable increases include Haotian International Investment (01341) at +1.61% (67.02%) and Junda Co., Ltd. (02865) at +1.43% (59.68%) [2]. Group 2: Companies with Decreased Holdings - Yihua Tong (02402) reported the largest decrease, down by 2.06% to 28.06% [2]. - Shandong Molong (00568) saw a reduction of 1.99%, with a current holding of 58.26% [2]. - Jihong Co., Ltd. (02603) decreased by 1.27%, now holding 57.37% [2]. - Other significant decreases include China Merchants Hengsheng Technology (03423) at -0.85% (3.15%) and CIFI Holdings Group (00884) at -0.82% (9.03%) [2]. Group 3: Five-Day Changes in Holdings - Junda Co., Ltd. (02865) had the highest five-day increase at +12.13%, reaching 59.68% [3]. - Nanhua Futures (02691) increased by 9.08% to 10.44% [3]. - Other notable increases include Baidu Biotechnology-B (02315) at +3.13% (22.65%) and Junshi Biosciences (01877) at +2.77% (55.84%) [3]. Group 4: Twenty-Day Changes in Holdings - Junda Co., Ltd. (02865) also led the twenty-day increase with +27.85%, holding 59.68% [4]. - Baidu Biotechnology-B (02315) increased by +14.85% to 22.65% [4]. - Other significant increases include Zhongwei New Materials (02579) at +11.72% (16.27%) and Youjia Innovation (02431) at +8.62% (14.46%) [4].

Core Viewpoint - The oral drug VV116, already approved for COVID-19 treatment, shows significant antiviral activity against the highly lethal Nipah virus, potentially providing a ready option for addressing future outbreaks [1][2][5]. Group 1: Research Findings - VV116 has demonstrated significant antiviral activity against two main strains of the Nipah virus (NiV-M and NiV-B) in vitro [2]. - In animal studies, administering VV116 at a dosage of 400 mg/kg increased the survival rate of infected golden hamsters to 66.7% and significantly reduced viral loads in key organs [4][5]. - The World Health Organization (WHO) classifies the Nipah virus as a high-priority regional threat, with a mortality rate ranging from 32% to 70% [5]. Group 2: Clinical Development and Market Potential - VV116 is a collaborative effort involving multiple research institutions and companies, with clinical development and commercialization responsibilities shared by Junshi Biosciences and Wangshan Wangshui [7]. - The drug has received emergency use authorization in Uzbekistan and conditional approval in China for COVID-19 treatment, indicating its potential for rapid deployment in public health emergencies [7][10]. - Wangshan Wangshui is actively pursuing the development of new indications for VV116, including potential applications for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) [9]. Group 3: Company Responses and Future Directions - Junshi Biosciences has stated that it is not currently conducting research on expanding VV116's indications for Nipah virus treatment, emphasizing the need for clinical data [11]. - In contrast, Wangshan Wangshui has expressed intent to monitor the Nipah virus situation closely and initiate clinical trials as necessary to address public health needs [11]. - The financial performance of Wangshan Wangshui has been impacted by the decline in demand for COVID-19 treatments, with significant losses reported in recent quarters [12].